BPC-157: Side Effects, Evidence, Legality and More, Answered

The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, made by chemical synthesis ^1,5. Other names include Body Protection Compound 157, PL 14736 and PLD-116. FDA noted that the name does not follow standard drug nomenclature ¹.

FDA's 2026 review found no approved product containing BPC-157 in any country ¹. For the full evidence record, see the BPC-157 reference page.

In chick embryo membranes, endothelial cells and rat limbs with blocked blood flow, BPC-157 was linked to more blood vessels ¹³. It also activated the VEGFR2-Akt-eNOS signalling pathway ¹³. In rat tendon fibroblasts, it increased growth hormone receptor expression ¹⁴.

In cultured tendon cells, it had no growth effect on its own. It did oppose growth inhibition caused by a toxic aldehyde ⁵. FDA added that dose-response relationships have not been established, which limits how much these findings can explain ¹.

Reviews of the animal work describe positive results across many rat injury models ^6,7. The reviews cited here are by the Zagreb group that first described BPC-157.

A 2025 systematic review of orthopaedic use found 36 studies, of which 35 were preclinical ¹². A 2026 systematic review counted three human studies totalling 30 people and rated their certainty very low ¹¹.

FDA counted five clinical studies in all ¹. They were a rectal-enema study in healthy volunteers (two meeting abstracts), a randomized, placebo-controlled colitis abstract and the three pilot reports ¹. In the colitis abstract, the difference from placebo was not statistically clear, and FDA judged the evidence insufficient ¹. No controlled human trial has shown that BPC-157 treats any condition.

In a rat Achilles tendon transection model, BPC-157 was associated with better biomechanical, functional and microscopic recovery than saline ⁵. This is an animal finding.

In the knee-pain chart review, 11 of 12 people given BPC-157 alone reported improvement by telephone. There was no control group and no validated function measure ⁸. A rotator cuff study is registered but not yet recruiting and has no results ¹⁸.

The published animal work concerns injured muscle, tendons, ligaments, bone, skin and the gut ^6,7. None of the human reports measured muscle mass or body weight ¹¹.

In an uncontrolled pilot, 12 women with interstitial cystitis all reported the highest score on a global response questionnaire ⁹. A two-person intravenous pilot measured blood markers and found no measurable change ¹⁰.

Without a control group, these pilot results cannot separate any effect of BPC-157 from placebo or natural recovery ¹¹. The one placebo-controlled trial, in ulcerative colitis, is known only from a meeting abstract ¹. Online photos and personal stories are not evidence. Our guide on why so much peptide evidence comes from animals explains how to read such claims.

The oral trial record (NCT02637284) planned single and repeated tablet use in healthy volunteers with placebo controls ¹⁵. No outcome data are available ^1,15.

A completed single-group study of a commercial BPC-157 gummy (NCT07752381, 40 participants) measured the blood inflammation markers hs-CRP and IL-6 ²⁰. It has posted no results and did not measure absorption ²⁰.

Pills, capsules and gummies sold as BPC-157 have no published human absorption data ¹. Our guide on why most peptides are injected explains why oral peptides are hard to absorb.

The interstitial cystitis pilot (12 women) and the intravenous pilot (2 adults) reported no adverse events ^9,10. These studies were tiny and uncontrolled, so they cannot rule out side effects ¹¹.

No study has looked at side effects in men or women separately. Forum reports cannot be checked and are not used here.

FDA lists BPC-157 among compounding substances that may present significant safety risks ². Its briefing described darkened skin and gums after use of a research-labelled product combining BPC-157 and TB-500, which recurred on re-use ¹. FDA judged the reaction likely due to the product but could not say which peptide caused it ¹.

A 2026 systematic review concluded that BPC-157 should not be used clinically outside regulated trials ¹¹. FDA also flagged unclear salt forms and missing data on impurities and microbial quality ¹.

FDA stated that dose-response relationships have not been established and that human pharmacokinetics are unknown ¹. For what human studies did and did not report, see BPC-157 dosage in human studies.

FDA's briefing cites supplier information for how long the powder and solution keep ¹. No study has defined how long reconstituted BPC-157 stays stable.

FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 on July 23, 2026, with ulcerative colitis as the use evaluated ³. The committee voted on whether it should be placed on the 503A compounding list ³. FDA has not published minutes or announced a decision, and the 503A list is unchanged ³.

FDA staff's briefing weighed against adding it, citing poor characterization, limited safety data and insufficient evidence that it works ¹. A staff briefing is input to the committee, not FDA's final word. FDA's May 2026 category document does not list BPC-157 in any category ¹⁷. Our article on FDA's 2025-2026 peptide compounding review explains the process.

FDA lists BPC-157 among substances whose compounding nominations were withdrawn, citing safety concerns ². An FDA advisory committee voted on it in July 2026, but FDA has announced no decision ³. Our guide to peptide legality in the United States explains research-use-only labelling.

No product is "best" by name. A useful certificate reports HPLC purity, mass-spectrometry identity, salt form, net peptide content and endotoxin ¹. See how to read a certificate of analysis.

See peptides and sport for how the list treats peptides ⁴.

The rat study randomised animals with repaired Achilles tendons to control, BPC-157, TB-500 or both ¹⁶. TB-500 alone reached a significant biomechanical difference from control; BPC-157 did not ¹⁶.

See the side-by-side table in BPC-157 vs TB-500. For tendons and injury, the full answer is in BPC-157 and TB-500 together: questions answered.

The rat Achilles tendon study found no added effect from combining the two ¹⁶. Its authors called the reason a hypothesis that needs confirmation ¹⁶.

We answer every question about the pair, including injury, dosage and the "Wolverine" name, in BPC-157 and TB-500 together: questions answered. The evidence summary is on the BPC-157 + TB-500 combination page.

The common blends are covered on the GLOW and KLOW combination pages. Evidence for one component does not transfer to a mixture ¹⁶. Our guide what are peptide blends? explains how to read component lists.

KPV reduced intestinal inflammation in cell lines and mouse colitis models ¹⁹. BPC-157's gut findings come from rats ⁷. For a full table, see BPC-157 vs KPV.

Laboratory animal studies were designed to model injury, not to set veterinary amounts ^6,7. A dosage chart for dogs has no regulatory or published clinical basis. For the human and animal evidence, see the BPC-157 reference page.